Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 39038267.
- Also identified by DOI 10.1200/JCO.24.00549 and PMC identifier 11458364.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sharing the burden of low-volume metastatic cancer between ICB and local treatments.
Medical subject headings
- Immune Checkpoint Inhibitors